The Latest Cardiac and Vascular News
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. “LivaNova delivered strong revenue and operating income growth in the third quarter” Post this Financial […]
LONDON–(BUSINESS WIRE)– #cardiacsurgery–LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
LONDON–(BUSINESS WIRE)– #cardiacsurgery–LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024. Makatsaria […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as […]
LONDON–(BUSINESS WIRE)– LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m. London time (8 a.m. Eastern Time). The Company will […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 First-quarter revenue of $263.4 million increased 9.7 percent on […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effective immediately, Chair of the Board William A. Kozy is appointed interim CEO to help the executive […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz […]
